Kellanova
K
NYSE
IPO1959
about K
Kellanova is a biopharmaceutical company focused on developing innovative gene therapy treatments for rare and genetic disorders, particularly targeting severe unmet medical needs such as hemophilia A.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $79.40 | $79.47 | $78.86 | $27.59B | 3.08M |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| +$0.86 | 20.97 | 8.64 | 13.67% | 9.46% | 2.94% |